Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis
Abstract Purpose Oncologists, clinical trialists, and guideline developers need tools that enable them to efficiently review the settings and results of previous studies testing metastatic breast cancer (MBC) drug therapies....
Main Authors: | Silberholz, John, Bertsimas, Dimitris, Vahdat, Linda |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer US
2021
|
Online Access: | https://hdl.handle.net/1721.1/131911 |
Similar Items
-
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis
by: Silberholz, John, et al.
Published: (2022) -
Emerging intrinsic therapeutic targets for metastatic breast cancer
by: Li, Jiawei, et al.
Published: (2023) -
Cost-Effectiveness of Adjuvant Trastuzumab Therapy for Early Breast Cancer in Asia: A Systematic Review
by: Abdul Rafar, Noor Razilah, et al.
Published: (2019) -
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
by: Nayar, Utthara, et al.
Published: (2020) -
Study metastatic properties of triple negative breast cancer cells.
by: Zhou, Yinning.
Published: (2013)